INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Atherosclerosis & Heart Disease desk →

1,829 studies · page 31 of 77

2024 / Narrative review

A review compares contemporary bariatric metabolic surgery and novel incretin mimetic therapies for managing obesity.

This review evaluates the advantages and disadvantages of modern pharmacologic and surgical weight management strategies for obesity. It examines data on anticipated weight loss, glycemic control, cardiometabolic improvements, and possible adverse outcomes associated with incretin-based drugs and bariatric metabolic surgery. The authors note that while lifestyle changes provide health benefits, weight loss from lifestyle alone is modest and hard to sustain.

Singh A, Nissen SE Diabetes Technol Ther, 2024. PMID 38669473

2024 / Narrative review

Approved obesity medications added to lifestyle interventions improve long-term weight loss and cardiometabolic risk factors over lifestyle interventions alone.

This narrative review synthesized data on the efficacy and safety of medications approved for long-term obesity management. Compared with lifestyle interventions alone, all approved obesity medications were more effective for long-term weight loss and cardiometabolic improvements. Older medications were associated with mean weight losses of 5-10%, while newer incretin analogues (semaglutide and tirzepatide) were linked to sustained mean reductions of 15-20%. The review notes challenges including cost, availability, weight regain, and loss of lean muscle and bone mineral density.

Qi QYD, Cox A, McNeil S, et al. Osteoarthr Cartil Open, 2024. PMID 38737985

2024 / Systematic review

Weight cycling impairs body composition, increases adipose inflammation, promotes pancreatic beta-cell fatigue, and escalates cardiovascular risk.

This systematic review evaluated the physiological impacts of repeated weight cycling. It found that multiple cycles of weight loss and regain increased central fat deposition, decreased lean mass during weight loss, and increased fat mass during regain. Weight cycling also enhanced adipose tissue inflammation, contributed to pancreatic beta-cell fatigue and failure through hyperinsulinemia and glucose fluctuations, and placed an additional burden on the cardiovascular system. Physical activity combined with calorie restriction was noted to help reduce metabolic disease and chronic inflammation.

Wang H, He W, Yang G, et al. Metabolites, 2024. PMID 38921478

2024 / Narrative review

Replacing meat with plant-based meat alternatives may improve several cardiovascular disease risk factors such as cholesterol levels and body weight.

This review evaluates the available literature on plant-based meat alternatives (PBMAs) and cardiovascular disease (CVD), including their nutritional profiles and impact on CVD risk factors. Compared with meat, PBMAs are usually lower in saturated fat and higher in polyunsaturated fat and dietary fibre. Dietary trials replacing meat with PBMAs have reported improvements in CVD risk factors, including total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B-100, and body weight. The authors note that long-term randomised controlled trials and prospective cohort studies evaluating CVD events are essential to draw more definitive conclusions.

Nagra M, Tsamkiranis F, Ward S, et al. Can J Cardiol, 2024. PMID 38934982

2024 / Review

Best-practice trans fat policies adopted in 43 countries protect 3.2 billion people and are estimated to prevent 66% of annual trans fat-related deaths.

This review summarizes progress following the 2018 WHO-partnered initiative to achieve global elimination of industrially produced trans fat (iTFA). Since 2018, 43 countries have adopted best practice regulations protecting an additional 3.2 billion people. Current policy coverage is estimated to prevent 66% of deaths attributed each year to trans fat in foods. However, companies continue to sell products containing iTFA in unregulated markets.

Steele L, Drummond E, Nishida C, et al. J Am Coll Cardiol, 2024. PMID 39111974

2024 / Narrative review

Common cholesterol-lowering dietary supplements have a limited clinical role due to inconsistent trial results and quality concerns.

This review evaluates common dietary supplements marketed for cholesterol reduction and cardiovascular benefits. Fish oil and niacin have a limited or negligible role in lipid management based on mixed findings, safety concerns, and major guidelines. While red yeast rice reduces LDL-C, and supplements such as garlic, phytosterols, psyllium, and berberine show modest LDL-C reductions, inconsistent study results and product quality issues persist. The authors conclude that these supplements have a limited role in clinical practice until they consistently match label claims and are free of contaminants.

Backes JM, Hilleman DE Am J Cardiovasc Drugs, 2024. PMID 39297910

2024 / Clinical review

A review estimates that heart-healthy diets combined with phytostanol ester could reduce 10-year coronary artery disease incidence by 23%.

This clinical review discusses the prevention of atherosclerotic cardiovascular diseases (ASCVDs) focusing on heart-healthy diets combined with dietary phytostanol fatty acid esters according to dyslipidaemia guidelines. Based on FINRISK and Cholesterol Treatment Trialists' Collaborators regression equations, combining heart-healthy diets with phytostanol ester lowers LDL-C enough to yield an estimated 23% reduction in 10-year coronary artery disease incidence. The authors note this strategy can help prevent subclinical atherosclerosis and its progression to ASCVD.

Simonen P, Nylund L, Vartiainen E, et al. Lipids Health Dis, 2024. PMID 39434087

2023 / Editorial / narrative review

An editorial argues that the medical profession has an ethical duty to advocate for whole-food plant-based nutrition to combat chronic cardiometabolic disease.

This editorial addresses the ethical, nutritional, and public health problems associated with the typical Western diet high in processed and animal-based foods. The authors state that animal-based foods drive mechanisms underlying chronic cardiometabolic disease, which whole-food plant-based nutrition can reverse. They also argue that factory farming contributes to climate change, antibiotic resistance, and infectious diseases, while nutritional resource distribution remains unjust. Consequently, the authors state that the medical profession has a duty to advocate for plant-based nutrition and nutrition equity.

Hull SC, Charles J, Caplan AL Am J Cardiol, 2023. PMID 36446227

2023 / Letter / narrative commentary

A commentary highlights the critical need to prevent vitamin B12 deficiency in individuals consuming plant-based, vegetarian, and vegan diets.

This letter discusses the necessity of vitamin B12 for individuals choosing plant-based diets, noting that unfortified plant foods are not a reliable source. Recent estimates suggest high rates of deficiency among vegetarian and vegan populations, especially pregnant women and women of child-bearing age. The authors note that deficiency is linked to increased risks of neuro, vascular, immune, and inflammatory disorders, and argue that current UK recommended nutrient intakes do not adequately address this deficit.

NANO counterpoint →

Niklewicz A, Smith AD, Smith A, et al. Eur J Nutr, 2023. PMID 36469110

2023 / Expert panel statement / narrative review

A German expert panel concluded observational data show no evidence that plasma phytosterol concentrations are linked to higher cardiovascular risk.

An expert panel assessed the potential atherogenicity of phytosterols (PSs) based on metabolism, animal, and human data. Consuming PS-enriched foods increases plasma PSs by ~35%, whereas homozygous phytosterolemia patients exhibit ~4000% higher concentrations where atherosclerosis prevalence is variable and may relate mainly to concomitant elevated LDL-C. Observational studies demonstrate no evidence linking plasma PS concentrations to increased atherosclerosis or cardiovascular events. Because PSs lower LDL-C without adverse safety signals, they offer a dietary approach to cholesterol management, though clinical benefits have not been established in long-term cardiovascular endpoint studies.

Windler E, Beil FU, Berthold HK, et al. Nutrients, 2023. PMID 36839186

2023 / Scientific statement / narrative review

Patterns like Mediterranean, DASH, pescetarian, and vegetarian strongly aligned with 2021 American Heart Association Dietary Guidance.

This American Heart Association scientific statement assessed the alignment of commonly practiced US dietary patterns with the 2021 AHA dietary guidance criteria. Several dietary patterns strongly aligned with the guidance, specifically Mediterranean, DASH, pescetarian, and vegetarian diets. The statement highlights that these patterns can be adapted to personal, cultural, and budgetary needs, and optimal cardiovascular health requires supporting food environments where food is prepared or consumed.

Gardner CD, Vadiveloo MK, Petersen KS, et al. Circulation, 2023. PMID 37128940

2023 / Narrative review

Inorganic phosphate food additives in ultra-processed foods may contribute to negative cardiorenal effects.

This review examines the potential role of inorganic phosphate food additives as contributors to the adverse effects of ultra-processed foods on cardiorenal disease. Inorganic phosphates are rapidly and efficiently absorbed, and elevated serum phosphate can directly lead to tissue or vessel calcification or indirectly act through mineral-regulating hormones like parathyroid hormone and fibroblast growth factor-23. While associations between serum phosphate, dietary phosphate intake, and mortality are noted in epidemiological studies, the exact magnitude of the role of these additives remains to be determined.

Shows an association, not proof of cause and effect.

Calvo MS, Dunford EK, Uribarri J Nutrients, 2023. PMID 37630701

2023 / Narrative review

A review outlines the benefits and uncertainties of new weight loss drugs, noting profound caloric reductions may warrant nutritional deficiency testing.

This review evaluates the pros and cons of newer weight loss medications like semaglutide and tirzepatide, noting short-term weight losses of -15% to -20% from baseline. The authors note that profound caloric reductions from these medications should prompt baseline or ongoing nutritional deficiency testing and dietary recommendations. However, long-term adherence, cost, access, supply chain issues, and long-term impacts on mental and physical health remain unknown.

Moyad MA Curr Urol Rep, 2023. PMID 37659049

2023 / Narrative review

A review outlines therapeutic milestones in obesity management, including leptin, melanocortin agonists, incretins, and metabolic surgery.

This review summarizes scientific milestones and therapies developed to address obesity and its cardiometabolic comorbidities. It highlights key developments starting from the discovery of leptin, melanocortin receptor agonists for syndromic obesity, incretin therapies including GLP-1 analogs and unimolecular combinations, and metabolic and bariatric surgery. The authors emphasize that this expanding therapeutic armamentarium warrants a coordinated multidisciplinary approach, such as cardiometabolic expertise centers, to address obesity and its complications.

Kokkorakis M, Katsarou A, Katsiki N, et al. Metabolism, 2023. PMID 37689110

2023 / Interdisciplinary, multi-stakeholder workshop proceedings

A multi-stakeholder workshop identified six research priorities regarding ultra-processed food intake, obesity, and cardiometabolic disease risk.

An interdisciplinary workshop brought together experts from government, academia, and industry to establish a Research Roadmap concerning processed food intake and obesity and cardiometabolic disease risk in the United States. Attendees highlighted challenges related to heterogeneity and subjectivity in ultra-processed food (UPF; Nova Group 4) classification. They developed six key research questions addressing objective UPF categorization, exposure assessment improvements, independence from diet quality, impacts on ingestive behavior, metabolic responses, and external environmental drivers. The authors conclude that further causal, mechanistic, and methodological research is warranted.

O'Connor LE, Higgins KA, Smiljanec K, et al. Adv Nutr, 2023. PMID 37722488

2023 / Commentary / expert opinion

Authors argue that policy action to reduce ultra-processed food consumption should not wait for complete understanding of cardiometabolic mechanisms.

Mathilde Touvier and colleagues argue that an incomplete understanding of the multiple mechanisms linking ultra-processed foods to cardiometabolic health should not delay public health policies aimed at reducing their consumption. No empirical data, study populations, or statistical findings are reported in the abstract.

Touvier M, da Costa Louzada ML, Mozaffarian D, et al. BMJ, 2023. PMID 37813465

2023 / Narrative review

Evidence indicates taurine may have beneficial cardiovascular effects and represents a candidate for anti-aging strategies.

This review summarizes scientific literature regarding the effects of taurine on human health, with a primary focus on aging and cardiovascular pathophysiology alongside metabolic regulation, neurological function, and athletic performance. Evidence from human and animal studies indicates potential cardiovascular benefits, including blood pressure regulation, enhanced vascular health, and improved cardiac fitness. Current recommendations for taurine intake and potential safety concerns were also addressed.

Santulli G, Kansakar U, Varzideh F, et al. Nutrients, 2023. PMID 37836520

2023 / Narrative review

Position papers from professional associations present conflicting views on the safety and adequacy of vegan diets for children and adolescents.

This narrative review examined position papers published by scientific, professional, and paediatric associations regarding vegan diets during infancy, childhood, and adolescence. Some associations support well-designed vegan diets with vitamin B12 supplementation and medical oversight, while others caution against them, citing potential harm, lack of substantiation, or reliance on lower-quality or outdated studies. The authors highlight the need for an up-to-date literature review and comparable assessments of both omnivorous and vegan diets.

Jakše B, Fras Z, Fidler Mis N Nutrients, 2023. PMID 38004109

2022 / Comprehensive review of human studies

A review indicates shellfish intake may raise hyperuricemia and gout risk, but may not increase risks of type 2 diabetes, heart disease, or thyroid cancer.

This comprehensive review synthesized available human studies evaluating the health benefits and risks of consuming shellfish, including mollusks and crustaceans. Findings showed that shellfish intake may increase the risk of hyperuricemia and gout, but may not increase the risk of type 2 diabetes, cardiovascular diseases, or thyroid cancer. Adequate evidence was lacking regarding associations with colorectal, pancreatic, and oral cancers, endometriosis, hip fracture, cognitive function, wheeze, eczema, and food allergy. Additionally, raw shellfish consumption may cause gastroenteritis and other infections from bacteria or viruses.

Shows an association, not proof of cause and effect.

Xu L, Cai J, Gao T, et al. Crit Rev Food Sci Nutr, 2022. PMID 33527847

2022 / Narrative review

GLP-1 receptor agonists are effective for obesity and T2DM, but their therapeutic effects are not fully congruent with endogenous GLP-1 actions.

This review examines the physiological functions of GLP-1 and its development into pharmaceuticals for obesity and type 2 diabetes (T2DM). GLP-1 receptor agonists are highlighted as effective anti-obesity agents and recommended second-line therapies for T2DM, particularly for patients with increased cardiovascular risk. The author discusses proglucagon processing across tissues and notes that the relationship between endogenous GLP-1 actions and the clinical effects of agonists is far from congruent and generally poorly understood.

Holst JJ J Intern Med, 2022. PMID 34982496

2022 / Statistical report / narrative review

The American Heart Association's 2022 Statistical Update compiles current data on heart disease, stroke, and cardiovascular risk factors.

The American Heart Association and the National Institutes of Health compiled the 2022 Statistical Update on heart disease, stroke, and cardiovascular risk factors. It covers core health behaviors such as diet, smoking, physical activity, and weight, as well as health factors including blood pressure, cholesterol, and glucose control. The 2022 edition adds an enhanced focus on social determinants of health, adverse pregnancy outcomes, vascular contributions to brain health, and the global burden of cardiovascular disease.

Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation, 2022. PMID 35078371

2022 / Narrative review

Piperine displays pleiotropic pharmacological properties and therapeutic benefits across various diseases according to clinical and preclinical data.

This review summarizes clinical and preclinical evidence regarding the molecular and pharmacological activities of piperine. According to the review, piperine demonstrates antioxidant, anticancer, anti-inflammatory, and antihypertensive properties, and provides therapeutic benefits in conditions including diabetes, obesity, cardiovascular diseases, kidney diseases, and hypertension. These effects are mediated through the modulation of various signaling molecules, enzymes, pathways, and the gut microbiota.

Tripathi AK, Ray AK, Mishra SK Beni Suef Univ J Basic Appl Sci, 2022. PMID 35127957

2022 / Narrative review

A review highlights that restoring NAD+ with nicotinamide mononucleotide shows therapeutic potential in age-related chronic conditions.

This review examines the importance of NAD+ in human aging and survival, its biosynthesis, clinical trial findings, and the role of nicotinamide mononucleotide (NMN). Systemic decline in NAD+ is linked to the hallmarks of aging and various age-related disorders. Studies in mice and humans indicate that NMN supplementation offers therapeutic potential for chronic conditions such as diabetes, cardiovascular issues, and cognitive impairment. The authors note that further human interventions are required to investigate the long-term effects of varying NMN doses.

Soma M, Lalam SK Mol Biol Rep, 2022. PMID 35441939

2022 / Narrative review

A review argues that statin therapy for primary cardiovascular prevention does not reduce mortality and has limited net benefit compared to lifestyle changes.

This review evaluates the evidence regarding statin therapy for the primary prevention of cardiovascular disease. The author states that prescribing statins to healthy patients without cardiovascular disease does not extend life and yields only a marginal reduction in ischemic event risk, while causing numerous side effects. In elderly patients, statin therapy shows no reduction in mortality or ischemic events and carries potential for significant harms. The review concludes that strategies should prioritize improving lifestyle factors rather than focusing on cholesterol levels and pharmacological intervention.

Durai V, Redberg RF Atherosclerosis, 2022. PMID 35934533